Recombinant Human Siglec-2/CD22 His-tag Avi-tag Protein, CF

In a functional ELISA, Biotinylated Recombinant Human Siglec-2/CD22 His-tag Avi-tag Protein (Catalog # AVI10191) binds to Human Siglec-2/CD22 Antibody (MAB19681) with an ED50 of 3.00-30.0 ng/mL.

2 μg/lane of Biotinylated Recombinant Human Siglec-2/CD22 His-tag Avi-tag (AVI10191) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 92-118 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Siglec-2/CD22 His-tag Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human Siglec-2/CD22 His-tag Avi-tag (Catalog # AVI10191) binds to Human Siglec-2/CD22 Antibody (Catalog # MAB19681) with an ED 50 of 3.00-30.0 ng/mL. Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. Kelm, S. et al. (1994) Current Biology 4:965. The ED 50 for this effect is 0.1-0.8 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Siglec-2/CD22 protein

  Human Siglec-2/CD22 (Asp20-Arg687) Accession # CAA42006.1

  GGGSGGGSGGGS

  HHHHHHH

  Avi-tag

  N-terminus

  C-terminus

• Accession #: CAA42006.1
• N-terminal Sequence: 79 kDa
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 79 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 92-118 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Siglec-2/CD22 His-tag Avi-tag Protein, CF

• B-cell receptor CD22
• BL-CAM
• B-lymphocyte cell adhesion molecule
• CD22 antigenMGC130020
• CD22 molecule
• CD22
• sialic acid binding Ig-like lectin 2
• Sialic acid-binding Ig-like lectin 2
• Siglec2
• Siglec-2
• SIGLEC2FLJ22814
• T-cell surface antigen Leu-14

Background

Siglecs are type I transmembrane proteins that belong to the immunoglobulin (Ig) superfamily and function as mammalian lectins (1). They are characterized by an extracellular domain consisting of various numbers of Ig domains with a conserved N-terminal V-set Ig ligand-binding domain. This binds species-specific sialic acid motifs on protein and lipid scaffolds to regulate intracellular signaling pathways (2). The cytoplasmic tail has signaling motifs, in most cases immunoreceptor tyrosine-based inhibitory motif (ITIM) (3). Human Siglec-2, also known as B cell antigen CD22 or B lymphocyte cell adhesion molecule (BL-CAM), is a B cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre B cells and on the surface of mature B cells. Two distinct human Siglec-2/CD22 cDNAs that arise from differential RNA processing of the same gene have been isolated. The predominant Siglec-2/CD22 beta encodes an 847 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V type domain, six Ig-like C2 type domains, a transmembrane region and a cytoplasmic tail with 4 immunoreceptor tyrosine-based inhibition motifs (ITIMs) (4). The variant Siglec-2/CD22 alpha encodes a 647 aa polypeptide missing two Ig-like C2 type domains and has a truncated (23 aa) cytoplasmic tail (5). Mature human Siglec-2 beta consists of a 668 amino acid (aa) extracellular domain (ECD), a 19 aa transmembrane segment, and a 141 aa cytoplasmic domain. Within the ECD, human Siglec-2 shares 59% and 58% aa sequence identity with the mouse and rat Siglec-2, respectively. Siglec-2/CD22 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells. Interaction of CD22 with trans ligands on opposing cells was found to be favored over the binding of ligands in cis (6). Besides its role as an adhesion molecule, Siglec-2/CD22 is a coreceptor that physically interacts with B-cell receptor (BCR) and is rapidly phosphorylated upon BCR ligation. It negatively regulates BCR signals by recruiting tyrosine phosphatase SHP-1 to its ITIMs. Phosphorylated Siglec-2/CD22 can also interact with other intracellular effector proteins such as Syk, PLC gamma, PI3 kinase and Grb-2, suggesting it may play a role in positive signaling (7-9). Another function of CD22 is that it mediates the anti-phagocytic effect of alpha 2,6-linked sialic acid, and inhibition of CD22 promotes the clearance of myelin debris, amyloid-beta oligomers and alpha -synuclein fibrils in vivo (10). CD22 also plays a role in autoimmunity and has great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) (11).

1. Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
2. Poe, J.C. and T.F. Tedder (2012) Trends Immunol. 33:413.
3. Meyer, S.J. et al. (2018) Front. Immunol. 9:2820.
4. Wilson, G.L et al. (1991) J. Exp. Med. 173:137.
5. Stamenkovic, I. and B. Seed (1990) Nature 345:74.
6. Collins, B.E. et al. (2004) Proc. Natl. Acad. Sci. 101:6104.
7. Crocker, P.R. and A. Varki (2001) Immunology 103:137.
8. Ravetch, J.V. and L.L. Lanier (2000) Science 290:84.
9. Wienands, Y.J. et al. (1999) J. Biol. Chem. 274:18769.
10. Pluvinage, J.V. et al. (2019) Nature. 5568:7751.
11. Clark, E.A. et al. (2018) Front. Immunol. 9:2235.

FAQs for Siglec-2/CD22 (AVI10191). (Showing 1 - 1 of 1 FAQ).

1. I am interested in buying a CD22 antibody for fluorescence microscopy and FACS I red on your web page that you also offer to label your antibodies, if required, is that correct?
   • We do have the ability to perform custom conjugations on certain antibodies, including some to the CD22 protein. If you send me the conjugate you are interested in I can provide you with a quote.

Bioinformatics

• Uniprot:
  • CAA42006.1()